ribavirin has been researched along with Infections, Coronavirus in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.90) | 18.2507 |
| 2000's | 3 (4.35) | 29.6817 |
| 2010's | 24 (34.78) | 24.3611 |
| 2020's | 40 (57.97) | 2.80 |
| Authors | Studies |
|---|---|
| de Wilde, AH; Jochmans, D; Neyts, J; Peters, HL; Posthuma, CC; Seley-Radtke, KL; Snijder, EJ | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Li, P; Shen, K; Su, X; Wang, Y | 1 |
| Ali, MAE; Habib, AMG; Mohammed, BS; Saquib, N; Taha, MAH; Zouaoui, BR | 1 |
| Abdulmomen, A; Al Harthy, A; Al Khatib, K; Al Mekhlafi, GA; Al Qasim, E; Al-Aithan, AM; Al-Dawood, A; Al-Hameed, F; Al-Omari, A; Al-Raddadi, R; Almotairi, A; Alraddadi, B; Arabi, YM; Balkhy, HH; Fowler, R; Gramish, JA; Hayden, FG; Jose, J; Kharaba, A; Mady, A; Maghrabi, K; Mandourah, Y; Merson, L; Qushmaq, I; Ragab, A; Shalhoub, S; Sindi, AA; Solaiman, O | 1 |
| Elfiky, AA | 1 |
| Chen, YK; Harypursat, V; He, XQ; Huang, YQ; Li, Y; Tang, SQ; Xu, XL; Zeng, YM | 1 |
| Martinez, MA | 2 |
| Wang, Y; Zhu, LQ | 1 |
| Cai, C; Cui, X; Guo, W; He, S; Wang, J; Xu, Y; Zhang, T; Zhao, X; Zheng, G; Zheng, J | 1 |
| Khalili, JS; Mak, NSA; Yan, Y; Zhu, H; Zhu, Y | 1 |
| Chan, MCW; Chen, D; Cheung, PP; Choy, KT; Chu, DKW; Huang, X; Hui, KPY; Kaewpreedee, P; Peiris, M; Sia, SF; Wong, AY; Yen, HL | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Chen, L; Chen, M; Huang, T; Huang, Z; Liu, L; Liu, M; Qiao, K; Wang, J; Xin, N; Zhang, G; Zhang, Z | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Chen, CP; Cheng, CY; Cheng, SH; Lee, YL; Liao, CH; Lin, YC; Liu, CE | 1 |
| Wan, Y; Wang, D; Wu, F; Zhang, L; Zhang, W | 1 |
| Chan, JMC; Chik, TSH; Choi, CYC; Lau, AWT; Lau, DPL; Leung, WS; Tsang, OTY | 1 |
| Shalhoub, S | 1 |
| Chan, J; Chan, JF; Chan, JW; Chan, KH; Chan, V; Chan, WM; Cheng, VC; Chu, AW; Chu, MY; Chung, TW; Fung, AY; Fung, K; Hung, IF; Ip, JD; Lau, CS; Law, WL; Lee, R; Leung, KH; Leung, WS; Lie, AK; Liu, R; Lo, J; Lung, DC; Lung, KC; Ng, AC; Ng, YY; Que, TL; Shum, HP; Sin, KM; Sin, S; Tam, AR; To, KK; Tsang, OT; Tso, EY; Wu, AK; Wu, TC; Yan, EY; Yan, WW; Yeung, A; Yeung, P; Yip, CC; Yuen, KY; Zhang, RR | 1 |
| Gao, P; Liu, M; Peng, H; Peng, J; Wang, Y; Xu, H; Xu, Q | 1 |
| He, J; Huang, D; Li, J; Liang, W; Liu, L; Xia, Z; Xu, X; Zhao, Y | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Amore, A; Bimonte, S; Cascella, M; Celentano, E; Crispo, A; Cuomo, A | 1 |
| Almasri, H; Ata, F; Sajid, J; Yousaf, Z | 1 |
| Bai, K; Chen, H; Fu, Y; Hu, J; Li, C; Liu, C; Liu, W; Qin, Y; Xu, F; Zhang, Q | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Li, C; Ren, L; Wang, L | 1 |
| He, K; Jia, Z; Shi, J; Song, X; Wang, W | 1 |
| Li, Z; Liu, Y; Wang, D | 1 |
| Carvalho Junior, RN; J C Neto, AM; Martins, AY; Reis, AF; S Costa, JF; Silva Arouche, TD | 1 |
| Chen, J; Jiang, J; Su, Y; Tong, S; Wang, S; Wu, C; Yu, Y | 1 |
| Gan, W; Gu, J; Li, H; Li, Y; Lu, C; Luo, P; Miao, H; Tian, M; Wang, J; Wang, S; Wu, M; Yao, Y; Yuan, B; Zhao, D; Zhao, X | 1 |
| Abbaspour Kasgari, H; Alikhani, A; Babamahmoodi, F; Davoudi Badabi, AR; Davoudi, L; Garratt, A; Hedayatizadeh Omran, A; Hill, A; Levi, J; Merat, S; Moradi, S; Saeedi, M; Shabani, AM; Simmons, B; Tirgar Fakheri, H; Wentzel, H | 1 |
| Bitaraf, S; Eslami, G; Esmaeilian, H; Freeman, J; Hajizadeh Farsani, M; Hill, A; Jafari Kashi, AH; Jelvay, S; Lotfi, Z; Marjani, S; Mobarak, M; Mobarak, S; Momtazan, M; Mousaviasl, S; Radmanesh, E; Sadeghi, A; Salmanzadeh, S; Simmons, B; Tabibi, R; Talebzadeh, SM; Wentzel, H; Wickramatillake, A | 1 |
| Brown, F; Cotton, MF; Decloedt, EH; Dodds, MG; Dron, L; Mills, EJ; Niranjan, V; Park, JJH; Rayner, CR; Reis, G; Smith, PF; Wesche, D | 1 |
| Jiang, Z; Li, W; Wang, Y; Xi, X; Zhu, Y | 1 |
| Hong, D; Shan, W; Zhao, Q; Zhu, J | 1 |
| Bahurupi, YA; Bandyopadhyay, A; Chikara, G; Moirangthem, B; Panda, PK; Saha, S; Singh, BC | 1 |
| Dunning, J; Ison, M; Lee, N | 1 |
| Hung, IF; Yuen, KY | 1 |
| Chung, EH; Jeong, I; Joh, JS; Kim, DW; Kim, G; Kim, SS; Kim, Y; Kim, YJ; Lee, JY; Yun, MR | 1 |
| Case, JB; Denison, MR; Graepel, KW; Lu, X; Sexton, NR; Smith, EC | 1 |
| Al-Tawfiq, JA; Hinedi, K | 1 |
| Estébanez, M; Membrillo, FJ; Ramírez-Olivencia, G; Ybarra, MDC | 1 |
| Eom, JS; Joo, YS; Jung, Y; Ko, JH; Lee, JS; Park, SY; Peck, KR; Shi, H; Son, JS; Woo, HJ | 1 |
| Baseler, L; Benecke, AG; Brining, D; Bushmaker, T; de Wit, E; Falzarano, D; Feldmann, F; Feldmann, H; Katze, MG; Martellaro, C; Munster, VJ; Okumura, A; Rasmussen, AL; Scott, DP | 1 |
| Chan, JF; Chan, KH; Chen, H; Dai, J; Hayden, FG; Kao, RY; Li, CP; Li, PT; Mok, FK; To, KK; Yuen, KY; Zheng, BJ | 1 |
| Adedeji, AO; Sarafianos, SG | 1 |
| Al-Tawfiq, JA; Dib, J; Memish, ZA; Momattin, H | 1 |
| Hui, DS; Memish, ZA; Zumla, A | 1 |
| Gomersall, CD; Leung, CH | 1 |
| Al Mobeireek, A; Al Mutairy, E; Al Rabiah, F; Butt, TS; Khalid, M; Khan, B | 1 |
| Coleman, CM; Frieman, MB | 1 |
| Abdul-Matin, M; Alaidaroos, AY; Albarrak, AM; Albarrak, MM; Almakhlafi, GA; Bahloul, A; Baig, K; Memish, ZA; Omrani, AS; Saad, MM | 1 |
| Haagmans, BL; Koopmans, MP; Koulouris, NG; Koutsoukou, A; Osterhaus, AD; Pontikis, K; Raj, VS; Spanakis, N; Tsakris, A; Tsiodras, S | 1 |
| Al-Jiffri, A; Farahat, F; Mushtaq, A; Shalhoub, S; Shamma, O; Siddiqi, N; Simhairi, R | 1 |
| Ling, Y; Luo, Y; Qu, R | 1 |
| Jang, HC; Jung, SI; Kee, SJ; Kim, UJ; Won, EJ | 1 |
| Wang, QY; Zheng, Y | 1 |
| Desforges, M; Liu, G; Shen, L; Talbot, PJ; Tan, W; Yang, Y; Ye, F | 1 |
| Fisher, D; Mo, Y | 1 |
| Ariza-Heredia, EJ; Chemaly, RF; Shahani, L | 1 |
| Christmann, D; Hansmann, Y; Hoen, B; Hustache-Mathieu, L; Lesens, O; Remy, V | 1 |
| Adamson, G; Bell, D; Biessels, P; Brookes, S; Fung, L; Ghanekar, A; Gorczynski, R; He, W; Koscik, C; Levy, A; Levy, GA; Ma, MX; McGilvray, ID; Ng, NF; Phillips, MJ; Rowe, A; Scrocchi, LA; Woods, C | 1 |
| Amici, C; Buonavoglia, C; Capobianchi, MR; Castilletti, C; Chiappa, L; Ciucci, A; Decaro, N; Di Caro, A; Martella, V; Santoro, MG | 1 |
| Brown, D; Cattral, M; Cole, E; Ding, JW; Fung, L; Gorczynski, R; Levy, G; Liu, MF; Ning, Q; Parodo, J; Phillips, MJ; Rotstein, O | 1 |
| Ding, JW; Fung, LS; Gorczynski, R; Leibowitz, J; Levy, GA; Liu, MF; Mosmann, T; Ning, Q; Pope, M; Rotstein, O | 1 |
16 review(s) available for ribavirin and Infections, Coronavirus
| Article | Year |
|---|---|
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Immunization, Passive; Interferon-beta; Lopinavir; Mice, Transgenic; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus | 2020 |
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indoles; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Male; Pandemics; Pharmaceutical Services; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Ribavirin; Risk Assessment; Severe Acute Respiratory Syndrome; Treatment Outcome | 2020 |
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Progression; Drug Administration Schedule; Gene Expression Regulation, Viral; Humans; Pandemics; Pneumonia, Viral; Ribavirin; RNA, Viral; SARS-CoV-2; Signal Transduction | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin | 2020 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Asymptomatic Diseases; Betacoronavirus; Biomarkers; Child; Clinical Laboratory Techniques; Coronavirus Infections; Cough; COVID-19; COVID-19 Testing; Drug Combinations; Early Diagnosis; Fever; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Ribavirin; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Use of ribavirin in viruses other than hepatitis C. A review of the evidence.
Topics: Adenoviridae Infections; Adenoviruses, Human; Antiviral Agents; Arenaviruses, New World; Clinical Trials as Topic; Coronavirus Infections; Hantavirus Infections; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, American; Hemorrhagic Fever, Crimean; Humans; Lassa Fever; Lassa virus; Meta-Analysis as Topic; Middle East Respiratory Syndrome Coronavirus; Orthohantavirus; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Ribavirin; Virus Diseases; Viruses | 2019 |
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
Topics: Age Distribution; Animals; Antiviral Agents; Camelus; Chiroptera; Coronavirus; Coronavirus Infections; Cross Infection; Diagnosis, Differential; Disease Progression; Female; Humans; Immunity, Innate; Infectious Disease Incubation Period; Interferons; Lung; Male; Middle East; Mycophenolic Acid; Public Health; Radiography; Real-Time Polymerase Chain Reaction; Ribavirin; Severe Acute Respiratory Syndrome; Sex Distribution; Viral Load | 2014 |
A review of treatment modalities for Middle East Respiratory Syndrome.
Topics: Antibodies, Viral; Antiviral Agents; Coronavirus Infections; Global Health; Humans; Immunologic Factors; Interferon-beta; Lopinavir; Ribavirin | 2016 |
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir | 2017 |
6 trial(s) available for ribavirin and Infections, Coronavirus
| Article | Year |
|---|---|
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protoc
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Interferon-alpha; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hong Kong; Hospitalization; Humans; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Hospitalization; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical Protocols; Combined Modality Therapy; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Hydroxychloroquine; India; Informed Consent; Lopinavir; Male; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Time Factors; Treatment Outcome | 2020 |
Indomethacin has a potent antiviral activity against SARS coronavirus.
Topics: Animals; Antiviral Agents; Aspirin; Cell Line; Chlorocebus aethiops; Coronavirus Infections; Coronavirus, Canine; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Feces; Humans; Indomethacin; Interferon-alpha; Ribavirin; RNA, Viral; Severe acute respiratory syndrome-related coronavirus; Virus Replication | 2006 |
47 other study(ies) available for ribavirin and Infections, Coronavirus
| Article | Year |
|---|---|
Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.
Topics: Acyclovir; Animals; Antiviral Agents; Chlorocebus aethiops; Coronavirus; Coronavirus Infections; Coronavirus NL63, Human; Drug Design; Humans; Middle East Respiratory Syndrome Coronavirus; Nucleosides; Severe acute respiratory syndrome-related coronavirus; Vero Cells; Virus Replication | 2015 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Clinical features, treatment and outcomes of an outbreak of type 7 adenovirus pneumonia in centralized residence young adults.
Topics: Adenoviruses, Human; Adolescent; Adult; China; Coronavirus Infections; Cough; Disease Outbreaks; Fever; Humans; Lung; Pandemics; Pneumonia; Pneumonia, Viral; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2022 |
Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Coronavirus Infections; Female; Hospital Mortality; Humans; Inpatients; Interferon-alpha; Logistic Models; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Pneumonia; Pneumonia, Viral; Polymerase Chain Reaction; Ribavirin; Saudi Arabia; Treatment Outcome | 2019 |
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.
Topics: Aged; Antiviral Agents; Coronavirus Infections; Critical Illness; Female; Humans; Intensive Care Units; Interferon alpha-2; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Pneumonia, Viral; Retrospective Studies; Ribavirin; RNA, Viral; Saudi Arabia; Treatment Outcome | 2020 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Catalytic Domain; Computational Biology; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Guanosine Monophosphate; Guanosine Triphosphate; Humans; Molecular Docking Simulation; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Ribavirin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Sofosbuvir; Thermodynamics; Uridine Triphosphate; Viral Proteins | 2020 |
Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period of COVID-19 pneumonia.
Topics: Ascorbic Acid; Betacoronavirus; Biomarkers; Ceftriaxone; Child; China; Clinical Laboratory Techniques; Convalescence; Coronavirus Infections; COVID-19; COVID-19 Testing; Drugs, Chinese Herbal; Feces; Humans; Interferons; Male; Pandemics; Patient Discharge; Pharynx; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimetabolites; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Emetine; Epithelial Cells; Homoharringtonine; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; SARS-CoV-2; Vero Cells; Virus Replication | 2020 |
Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease.
Topics: Adult; Antiviral Agents; Betacoronavirus; Conjunctivitis, Viral; Coronavirus Infections; COVID-19; Humans; Male; Nasal Cavity; Ophthalmic Solutions; Pandemics; Pharynx; Pneumonia, Viral; Ribavirin; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Taiwan; Virus Shedding | 2020 |
Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.
Topics: Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Combinations; Female; Humans; Lopinavir; Middle Aged; Pandemics; Patient Discharge; Pneumonia, Viral; Ribavirin; Ritonavir; RNA, Viral; SARS-CoV-2 | 2020 |
Presumed COVID-19 index case on diamond princess cruise ship and evacuees to Hong Kong.
Topics: Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; Hong Kong; Humans; Japan; Lopinavir; Male; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Ships; Travel | 2020 |
Interferon beta-1b for COVID-19.
Topics: Adjuvants, Immunologic; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Interferon beta-1b; Lopinavir; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes.
Topics: Adolescent; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; China; Coronavirus Infections; COVID-19; Disease Susceptibility; Female; Hospitals, Pediatric; Humans; Infant; Interferon-alpha; Length of Stay; Male; Pandemics; Pediatricians; Pneumonia, Viral; Proportional Hazards Models; Retrospective Studies; Ribavirin; SARS-CoV-2; Severity of Illness Index | 2020 |
SARS-CoV-2 persisted in lung tissue despite disappearance in other clinical samples.
Topics: Aged; Antiviral Agents; Betacoronavirus; Blood Loss, Surgical; Blood Volume; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Extracorporeal Membrane Oxygenation; Fatal Outcome; Humans; Hypertension; Lung; Lung Transplantation; Male; Oseltamivir; Pandemics; Pneumonia, Viral; Respiration, Artificial; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed; Virus Shedding | 2020 |
COVID-19 presenting with diarrhoea and hyponatraemia.
Topics: Abdominal Pain; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Darunavir; Diagnosis, Differential; Diarrhea; Humans; Hyponatremia; Male; Pandemics; Pneumonia, Viral; Ribavirin; SARS-CoV-2; Treatment Outcome | 2020 |
Clinical Analysis of 25 COVID-19 Infections in Children.
Topics: Adolescent; Age Factors; Antiviral Agents; Betacoronavirus; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; Child, Preschool; China; Coronavirus Infections; Cough; COVID-19; Female; Fever; Humans; Infant; Lopinavir; Lymphocyte Count; Male; Pandemics; Pneumonia, Viral; Prognosis; Retrospective Studies; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).
Topics: Antiviral Agents; Betacoronavirus; Bronchoalveolar Lavage Fluid; Cell Degranulation; Coronavirus Infections; COVID-19; Drug Repositioning; Endocytosis; Gene Expression Profiling; Humans; Lysosomes; Molecular Docking Simulation; Neutrophil Activation; Pandemics; Pneumonia, Viral; Ribavirin; Saquinavir; SARS-CoV-2; Transcriptome | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drug Interactions; Humans; Hydrogen Bonding; Hydroxychloroquine; Ligands; Molecular Docking Simulation; Nanotechnology; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Static Electricity; Viral Nonstructural Proteins | 2020 |
Ribavirin therapy for severe COVID-19: a retrospective cohort study.
Topics: Adrenal Cortex Hormones; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Immunoglobulins; Male; Middle Aged; Pandemics; Patient Discharge; Pneumonia, Viral; Retrospective Studies; Ribavirin; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome | 2020 |
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Drug Therapy, Combination; Epidemiologic Research Design; Humans; Interferon beta-1b; Lopinavir; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Meta-Analysis as Topic; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Research Design; Ribavirin; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Systematic Reviews as Topic; Treatment Outcome | 2020 |
Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Algorithms; Bayes Theorem; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Data Mining; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferons; Male; Middle Aged; Neural Networks, Computer; Odds Ratio; Pandemics; Patient Safety; Pneumonia, Viral; Ribavirin; Young Adult | 2020 |
Early triple antiviral therapy for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Interferon beta-1b; Lopinavir; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Early triple antiviral therapy for COVID-19 - Authors' reply.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Interferon beta-1b; Lopinavir; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015.
Topics: Aged; Antiviral Agents; Coronavirus Infections; Disease Outbreaks; Humans; Infection Control; Male; Middle East; Middle East Respiratory Syndrome Coronavirus; Phylogeny; Republic of Korea; Ribavirin; Saudi Arabia | 2017 |
Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations.
Topics: Animals; Antiviral Agents; Azacitidine; Cell Line; Coronavirus; Coronavirus Infections; Exoribonucleases; Genetic Fitness; Genome, Viral; Genotype; Mice; Mutation; Phenotype; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Virus Replication | 2017 |
The calm before the storm: clinical observations of Middle East respiratory syndrome (MERS) patients.
Topics: Antiviral Agents; Coronavirus Infections; Humans; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Prognosis; Ribavirin; Saudi Arabia | 2018 |
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
Topics: Adult; Aged; Antiviral Agents; Coronavirus Infections; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Incidence; Lopinavir; Male; Post-Exposure Prophylaxis; Retrospective Studies; Ribavirin; Ritonavir; Young Adult | 2019 |
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.
Topics: Animals; Antiviral Agents; Coronavirus; Coronavirus Infections; Interferon alpha-2; Interferon-alpha; Macaca mulatta; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Virus Replication | 2013 |
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Communicable Diseases, Emerging; Coronavirus; Coronavirus Infections; Disease Outbreaks; Drug Discovery; High-Throughput Screening Assays; Humans; Interferons; Mycophenolic Acid; Ribavirin; Vero Cells; Viral Load; Viral Plaque Assay | 2013 |
Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection.
Topics: Animals; Antiviral Agents; Cell Line; Coronavirus Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Respiratory Tract Infections; Ribavirin | 2013 |
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Coronavirus; Coronavirus Infections; Critical Illness; Diabetes Mellitus; Female; Humans; Hypertension; Imipenem; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Renal Insufficiency, Chronic; Respiration, Artificial; Respiratory Tract Infections; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Middle East respiratory syndrome.
Topics: Acute Kidney Injury; Algorithms; Antiviral Agents; Coronavirus Infections; Critical Care; Critical Illness; Humans; Interferons; L-Lactate Dehydrogenase; Lymphopenia; Protective Clothing; Respiration, Artificial; Ribavirin; Thrombocytopenia | 2014 |
Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.
Topics: Adult; Antiviral Agents; Coronavirus Infections; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Polyethylene Glycols; Radiography; Recombinant Proteins; Ribavirin; Viral Load | 2015 |
Treating MERS-CoV during an outbreak.
Topics: Antiviral Agents; Coronavirus Infections; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle East Respiratory Syndrome Coronavirus; Recombinant Proteins; Ribavirin | 2014 |
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Coronavirus Infections; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Recombinant Proteins; Retrospective Studies; Ribavirin; Saudi Arabia; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.
Topics: Antiviral Agents; Coronavirus Infections; Drug Combinations; Drug Therapy, Combination; Greece; Humans; Lopinavir; Male; Middle East Respiratory Syndrome Coronavirus; Phylogeny; Respiratory Tract Infections; Ribavirin; Ritonavir; Viremia; Virus Shedding | 2014 |
IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Coronavirus Infections; Drug Therapy, Combination; Female; Humans; Interferon-alpha; Interferon-beta; Lung; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Plasma; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2015 |
[Clinical analysis of the first patient with imported Middle East respiratory syndrome in China].
Topics: Adult; Antiviral Agents; Back Pain; Blood Gas Analysis; China; Coronavirus Infections; Humans; Leukocyte Count; Lung; Male; Middle East Respiratory Syndrome Coronavirus; Monitoring, Physiologic; Oxygen; Pleural Effusion; Republic of Korea; Ribavirin; Sputum | 2015 |
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Topics: Antiviral Agents; Coronavirus Infections; Drug Therapy, Combination; Humans; Interferon-alpha; Lopinavir; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Republic of Korea; Ribavirin; Ritonavir | 2016 |
[Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV].
Topics: Antiviral Agents; Computational Biology; Coronavirus Infections; Drug Therapy, Combination; Gene Targeting; Humans; Interferon-alpha; Middle East Respiratory Syndrome Coronavirus; Ribavirin; Signal Transduction | 2016 |
Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene.
Topics: Antiviral Agents; Cell Line; Chloroquine; Coronavirus Infections; Coronavirus OC43, Human; Genes, Reporter; HEK293 Cells; Humans; Luciferases; Respiratory Tract Infections; Ribavirin; Virus Replication | 2016 |
[Severe acute respiratory syndrome (SARS). The questions raised by the management of a patient in Besançon and Strasbourg].
Topics: Aircraft; Anti-Inflammatory Agents; Antiviral Agents; China; Coronavirus; Coronavirus Infections; Diagnosis, Differential; Disease Outbreaks; Drug Therapy, Combination; France; Humans; Hydrocortisone; Lung; Male; Middle Aged; Patient Isolation; Patient Readmission; Polymerase Chain Reaction; Ribavirin; Severe Acute Respiratory Syndrome; Tomography, X-Ray Computed; Travel | 2003 |
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity.
Topics: Animals; Antiviral Agents; Coronavirus Infections; Drug Delivery Systems; Female; Hepatitis, Viral, Animal; Hepatocytes; Liver Failure, Acute; Macrophages; Mice; Mice, Inbred BALB C; Murine hepatitis virus; Outcome Assessment, Health Care; Ribavirin; Virus Replication | 2006 |
Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.
Topics: Animals; Coronavirus Infections; Cytokines; Female; Fibrinogen; Injections, Intraperitoneal; Interleukin-1; Macrophages, Peritoneal; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Inbred C3H; Murine hepatitis virus; Ribavirin; RNA, Messenger; Th1 Cells; Th2 Cells; Thromboplastin; Transcription, Genetic; Tumor Necrosis Factor-alpha | 1998 |
Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Cells, Cultured; Coronavirus Infections; Female; Immunity, Innate; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Murine hepatitis virus; Ribavirin; Th1 Cells; Th2 Cells | 1998 |